Anazawa, Y., H. Nakagawa, M. Furihara, S. Ashida, K. Tamura, H. Yoshioka, T. Shuin, T. Fujioka, T. Katagiri, and Y. Nakamura. 2005. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. Cancer Res. 65(11):4578-4586.

Andersen, M.E., H.J. Clewell III, M.L. Gargas, F.A. Smith, and R.H. Reitz. 1987. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87(2):185-205.

Anderson, N.L., and N.G. Anderson. 2002. The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell Proteomics 1(11):845-867.

Anderson, N.L., N.G. Anderson, L.R. Haines, D.B. Hardie, R.W. Olafson, and T.W. Pearson. 2004. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J. Proteome Res. 3(2):235-244.

Ando, Y., and Y. Hayashizaki. 2006. Restriction landmark genomic scanning. Nat. Protoc. 1(6):2774-2783.

Andrew, A.S., A.J. Warren, A. Barchowsky, K.A. Temple, L. Klei, N.V. Soucy, K.A. O'Hara, and J.W. Hamilton. 2003. Genomic and proteomic profiling of responses to toxic metals in human lung cells. Environ. Health Perspect. 111(6):825-835.

Andrews, L.B. 2005. Harnessing the benefits of biobanks. J. Law Med. Ethics 33(1):22-30.

Antoniadis, A., S. Lambert-Lacroix, and F. Leblanc. 2003. Effective dimension reduction methods for tumor classification using gene expression data. Bioinformatics 19(5):563-570.

Anway, M.D., A.S. Cupp, M. Uzumcu, and M.K. Skinner. 2005. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 308(5727):1466-1469.

Arbour, N.C., E. Lorenz, B.C. Schutte, J. Zabner, J.N. Kline, M. Jones, K. Frees, J.L. Watt, and D.A. Schwartz. 2000. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25(2):187-191.

Ausness, R.C. 2002. Will more aggressive marketing practices lead to greater tort liability for prescription drug manufacturers? Wake Forest Law Rev. 37(1):97-139.

Azmi, J., J.L. Griffin, H. Antti, R.F. Shore, E. Johansson, J.K. Nicholson, and E. Holmes. 2002. Metabolic trajectory characterisation of xenobiotic-induced hepatotoxic lesions using statistical batch processing of NMR data. Analyst 127(2):271-276.

Bae, D.S., W.H. Hanneman, R.S. Yang, and J.A. Campain. 2002. Characterization of gene expression changes associated with MNNG, arsenic, or metal mixture treatment in human keratinocytes: Application of cDNA microarray technology. Environ. Health Perspect. 110(Suppl. 6):931-941.

Baggerly, K.A., K.R. Coombes, K.R. Hess, D.N. Stivers, L.V. Abruzzo, and W. Zhang. 2001. Identifying differentially expressed genes in cDNA microarray experiments. J. Comput. Biol. 8(6):639-659.

Baggerly, K.A., J.S. Morris, and K.R. Coombes. 2004. Reproducibility of SELDI-TOF protein patterns in serum: Comparing datasets from different experiments. Bioinformatics 20(5):777-785.

Baggerly, K.A., J.S. Morris, S.R. Edmonson, and K.R. Coombes. 2005. Signal in noise: Evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl. Cancer Inst. 97(4):307-309.

Bailey, W.J., and R. Ulrich. 2004. Molecular profiling approaches for identifying novel biomarkers. Expert. Opin. Drug Saf. 3(2):137-151.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement